Genomatix Achieves GeneChip-compatible™ Status with Affymetrix GeneChip® Microarray Platform
News Nov 30, 2005
Genomatix Software GmbH has announced that it has achieved GeneChip-compatible™ status for several products with the Affymetrix Inc. GeneChip® microarray platform and that it has joined Affymetrix GeneChip-compatible Applications Program, which provides customers with a broad spectrum of software solutions for biomedical research and development.
As a GeneChip-compatible software provider, Genomatix is committed to integrating its entire microarray analysis pipeline with the Affymetrix technology.
The Genomatix line of products which achieved GeneChip-compatible™ status consists of ChipInspector, ChipInspector TL, ElDorado, GEMS Launcher, and BiblioSphere PathwayEdition.
With those products Genomatix provides a broad set of solutions for Affymetrix GeneChip users, including analysis of data from Affymetrix whole-genome tiling and exon arrays.
"We are proud of having met the high standards of Affymetrix and earning GeneChip-compatible™ status," said Klaus May, Director of Sales and Marketing at Genomatix.
"The tight integration of our microarray analysis pipeline with the Affymetrix platform will stimulate exciting new results in both basic and applied biomedical R&D."
"Especially in conjunction with the new Affymetrix tiling and exon array technology, I expect that our tools will drive far greater understanding of genomic organization and transcriptome regulation."
"Affymetrix is pleased to be working with Genomatix in their efforts to develop advanced tools for analyzing GeneChip data," said Steve Lincoln, vice president of Informatics at Affymetrix.
"We are particularly excited to see the emergence of next-generation commercial software which can help bring unprecedented levels of genomic resolution into the hands of applied biomedical researchers."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.